ArticleBlood2009
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 164 citations in OpenAlex.
- Pooled it
- Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.Journal for immunotherapy of cancer · 2022Trial
- Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.Annals of hematology · 2022Trial
- Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2019Trial
- A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.American journal of hematology · 2017Trial
- Trial
- Trial
- Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.Oncoimmunology · 2026Article
- Retrospective analysis of the association between monocyte percentage and outcomes in newly diagnosed diffuse large B-cell lymphoma.Oncology letters · 2026Article
- Bacillus cell‑free supernatants support canine epithelial barrier function and stress adaptation through anti-inflammatory and anti-apoptotic mechanisms.Journal of animal science · 2026Article
- Cellular interaction of mycosis fungoides tumor cells changes from cytotoxic CD8+ T cells in plaques to B cells in tumors.Frontiers in immunology · 2026Article
- Single-cell sequencing reveals the complexity of cutaneous T-cell lymphoma.Discover oncology · 2025Review
- Angiogenesis and lymphangiogenesis in primary cutaneous lymphomas: a narrative review.Clinical and experimental medicine · 2025Review
- Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling.Journal of advanced research · 2025Article
- A silence catalyst: CCL5-mediated intercellular communication in cancer.Archives of toxicology · 2025Review
- Article
- Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.Haematologica · 2025Article
- Review
- Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer.Journal of cancer research and clinical oncology · 2024Article
- How lactate affects immune strategies in lymphoma.Frontiers in molecular biosciences · 2024Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
A variety of nonmalignant cells present in the tumor microenvironment promotes tumorigenesis by stimulating tumor cell growth and metastasis or suppressing host immunity. The role of such stromal cells in T-cell lymphoproliferative disorders is incompletely understood. Monocyte-derived cells (MDCs), including professional antigen-presenting cells such as dendritic cells (DCs), play a central role in T-cell biology. Here, we provide evidence that monocytes promote the survival of malignant T cells and demonstrate that MDCs are abundant within the tumor microenvironment of T cell-derived lymphomas. Malignant T cells were observed to remain viable during in vitro culture with autologous monocytes, but cell death was significantly increased after monocyte depletion. Furthermore, monocytes prevent the induction of cell death in T-cell lymphoma lines in response to either serum starvation or doxorubicin, and promote the engraftment of these cells in nonobese diabetic/severe combined immunodeficient mice. Monocytes are actively recruited to the tumor microenvironment by CCL5 (RANTES), where their differentiation into mature DCs is impaired by tumor-derived interleukin-10. Collectively, the data presented demonstrate a previously undescribed role for monocytes in T-cell lymphoproliferative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.